Phenotypic alterations occur when resting human B lymphocytes become germinal center (GC) cells. These include the induction of surface CD38, CD95 (FAS/APO-1), and carboxypeptidase-M (CPM), a recently described GC marker. However, the factors that govern the in vivo induction of these surface molecules on B cells remain unknown. Here, we purified resting (CD38-) human B lymphocytes from tonsils in an attempt to establish culture conditions resulting in the induction of these three GC markers. We show that interferon (IFN) 0t or IFN-% as well as antibodies against the B cell antigen receptor (BCR), could induce CD38 on resting B lymphocytes, a phenomenon further enhanced by CD40 stimulation. Concomitantly, CD95 was upregulated by CD40 ligation and, to a lesser extent, by IFN-% By contrast, CPM expression could be upregulated only through BCR triggering. This CPM induction was specifically enhanced by CD19 or CD40 ligation. CD40 + BCR stimulation of resting B cells with CD40 ligand-transfected fibroblastic cells in the presence of cross-linked anti-BCIL monoclonal antibodies resulted in the coexpression of CD38, CD95, and CPM. As GC cells, these cells also expressed CD71, CD80 (B7.1), and CD86 (B7.2), but not CD24. However, CD10 + or CD44-B cells could not be detected in these culture conditions, suggesting that yet other signals are required for the induction of these GC markers. Consistent with a GC phenotype, CD40 + BCR~timulated cells exhibited reduced viability when cultured for 20 h in the absence of stimulus. These results first demonstrate that cotriggering of resting B ceUs through BCR and CD40 induces both phenotypic and functional GC features. They also show that IFN and CD19 triggering of resting B cells specifically modulate the expression of GC markers.
A
fter antigenic challenge, a large variety of cells sequentially cooperate to develop the humoral response. APC take up the antigen, process it, and present it to specific Th cells in the context of MHC class II molecules. This cognate interaction drives Th cells to express both membrane-associated and soluble factors that control the proliferation and differentiation of B lymphocytes. In secondary lymphoid organs, this Th-B cell interaction is a prerequisite for the fomlation of germinal centers (GC), l the histological structures where B lymphocytes proliferate and mature into high-affinity memory cells (for reviews see references 1, 2).
In humans, several phenotypic alterations occur when B lymphocytes enter GC. These include both induction and disappearance of various surface molecules (CD markers) that most likely reflect B cell activation and adaptation to a new environment. Among GC markers, CD38 is a surface enzyme catalyzing the synthesis of cADP-ribose from NAD (3) (4) (5) (6) (7) . CD38 is believed to participate in the control of GC B cell growth (4) or viability (8) and is coexpressed on GC cells with the carboxypeptidase M (CPM), a zincdependent protease known to cleave offbasic COOH-terminal amino acids from hormonal peptides (9) . In addition to these two ectoenzymes, GC cells express on their surface CD95 (FAS), a TNF receptor-related molecule that also participates in the control of GC B cell survival (10, 11) .
Here, we attempted to establish culture conditions resulting in the induction of a GC phenotype on resting tonsillar B cells. This approach allowed us to show that dual triggering of CI)40 and B cell antigen receptor (BC1L) is required for the coexpression of CD9S, CD38, and CPM. It also showed that cells coexpressing these markers are highly susceptible to spontaneous cell death. Finally, it is suggested that IFNs as well as CD19 triggering contribute to the in vivo acquisition of a GC phenotype. B Cell Cultures. All cultures were perforated in RPMI 1640 medium enriched with 2 mM t-glutamine (Gibco Laboratories, Grand Island, NY), 10% heat-inactivated FCS (Flow Laboratories, &vine, Scotland), 80 Ixg/ml gentamicin (Gencalline; Schering-Plough), in the presence of irradiated (7,00()-rad) CD32-transfected (CD32-L cells; American Type Culture Collection, 16.2 CG7) or CD40-L/CD32-double transfected routine Ltkcells. The CD40-L/CD32-double transfected L cells were produced in our laboratory. Cultures were set up in flat-bottomed 96-well microtiter plates (100 txl final volume) in the presence of 5 • 103 transfected L cells/well and 104-105 purified B cells. Anti-CD or anti-BCR were used at 2 Ixg/ml or 1 : 1,000 dilution ofascitic fluid throughout this study.
B Cell Purification. Tonsillar mononuclear cells were separated by standard Ficoll-Hypaque gradient method and were next submitted to E rosetting with SfLBC. The following procedure was designed according to Lagresle et al. (14) . Nonrosetting cells were labeled with anti-T cell (anti-CD2, -CD3, -CD4, and -CD8 mAbs), anti-monocyte (anti-CD14 mAb), and anti-CD38 (OKT10) mAbs and subsequently incubated twice with magnetic beads coated with anti-mouse lgG antibodies (Dynal, Oslo, Norway). Labeled cells were removed by applying a magnetic field for 15 min. The purity of the B cell subpopulation obtained after this procedure was >98% as estimated by FACScan | inmmnofluorescence labelings performed with CD2, CD3, CD4, CDI9, CD38, and CD44 mAbs. For triple-labeling experiments, cells were labeled by biotinylated goat-anti-IgD antibody + tricolor-streptavidin and indirect mAb + PE-conjugated anti-mouse antibody. After saturation with mouse serum, FITC-conjugated anti-CD38 was added.
Results

CD38-Tonsillar B Cells Indude Both Naive and Memory B
Cells. The phenoWpe of highly purified tons/liar B cells was assessed using triple labeling with (a) anti-CD38 (FITC), (b) anti-IgD (Tricolor), and (c) PE-conjugated anti-CD20, anti-CD95 (FAS), anti-CPM, anti-CD71, anti-CD80 (B7.1), anti-CD86 (B7.2), anti-CD24, anti-CD10, or anti-CD44 mAbs. Results are shown in Fig. 1 ,'1. From these labelings, two different tonsillar B cell subsets can be distinguished: (a) CD38 l~ cells, which are resting and include both slgD + naive and slgD-memory cells (gate R1) (14-16); and (b) CD38 h~gh cells, which correspond to GC B lymphocytes. Consequently, in this report, resting tonsillar B cells were selected by CD38 depletion (14) . As expected, the resulting population ( Fig. 1 B) wpically included variable proportions of slgD-" cells. CD38--purified B cells also expressed low levels of CD95, CD80, CD86, and CD71, and no CPM, but high levels of CD24 and CD44 antigens. (Fig. 2 A) . This IFN-mediated CD38 induction was observed at as early as 18 h of culture and reached near maximal levels after 24 h (Fig. 2 A) . The IFN-c~ and IFN-',/-mediated induction of CD38 was a dose-dependent process with a half-maximal effect observed at "-~5 and ,'-~1 U and an optimal effect at N1,200 and "~300 U, respectively ( Fig. 2 B) . This induction was a direct effect of IFNs on B cells because it could be seen in the absence of fibroblastic CD32-L cells (not shown). Triggering of BC1K by immobilized anti-K+K light chain mAbs was also found to induce a moderate expression of CD38. This anti-BC1K-induced CD38 expression displayed slower kinetics than that observed with IFN-(x and IFN-~/with an optimal expression around day 5 ( Fig. 2 A) . At this time point, 22 -Z_ 9% (n = 3) of cells expressed CD38. In contrast, although it is the most efficient mitogenic signal, CD40 triggering by immobilized anti-CD40 mAb (mAb 89) essentially failed to turn on CD38 expression (Fig. 2 A) . shown as a double entry table with CD38 labeling FACS | profdes obtained for each combination (Fig. 3) . CD40 stimulation significantly enhanced B C R -i n d u c e d expression o f CD38. Similarly, IFN-c~-or I F N -y -d r i v e n expression of CD38 could be further enhanced by CD40 stimulation. Moreover, combined stimulation o f l F N s and anti-BCR or IFN-o~ and I F N -y displayed synergistic effects on CD38 expression. Thus, CD40 stimulation of resting tonsillar B lymphocytes could enhance a n t i -B C R -or IFN-induced expression of CD38.
IFN-o6 IFN-T, or BCR Ligation
IFN-or BCR-induced Expression of CD38 Is Further En
CD40 Triggering or IFN-T Upregulate CD95 (FAS) on the Suface of Resting B Lymphocytes. GC B cells coexpress CD38
and CD95 antigens; thus, we examined whether CD95 expression would be upregulated in vitro on C D 3 8 -B cells. Consistent with previous studies (10, 11, 18) , only anti-CD40 and I F N -y significantly enhanced surface CD95 expression on C D 3 8 -B cells after a 3-d culture period, whereas IFN-~x remained virtually inactive (Fig. 4) the presence o f C P M on the surface of CD38 + leukocytes (9) . A m o n g mature B lymphocytes, only GC cells expressed this ectoenzyme (Fig. 1) . Moreover, as well as CD38 and CD95, in vivo expression o f C P M appears to be an early event of B cell activation inasmuch as this enzyme is expressed on early (slgD +) unmutated GC cells (Lebecque, S., O. de Bouteille, C. Arpin, J. Banchereau, and Y.-J. Liu, manuscript in preparation). In vitro, neither CD40 stimulation nor 16 tested cytokines (see above), used alone or in combination, could induce C P M expression on C D 3 8 -B cells (Fig. 5) . B C R triggering was thus the only efficient stimulus able to induce surface C P M expression on C D 3 8 -tonsillar B cells. Indeed, as shown in Fig. 5 , a fraction (13 + 4%, n = 4) o f C D 3 8 -B lymphocytes cultured in the presence o f cross-linked a n t i -B C R were induced to express CPM. This induction could be observed as soon as day 3 and increased up until day 6 (not shown). Anti-BCR--induced expression o f C P M was significantly enhanced by anti-CD40 mAb and to a lesser extent by IFN-or (Fig. 5) . In contrast, I F N -y partially counteracted the induction of CPM. W h e n analyzing other costimulatory antibodies, it was found that anti-CD19 mAbs were also capable of enhancing the a n t i -B C R -i n d u c e d expression of CPM. As shown in Fig. 6, A and B, the anti-CD 19 mAbs and the anti-CD40 mAbs strongly enhanced anti-B C R -i n d u c e d expression of CPM, thus confirming the specific role o f these molecules. Anti-CD21 mAbs stimulated slightly but reproducibly a n t i -B C R -i n d u c e d C P M expression (Fig. 6, A and B) . In contrast, antibodies specific for CD20, CD22, H L A -D R , and CD81 failed to enhance the expression of C P M on anti-BCR-activated B cells. The enhancing effect o f CD40 ligand or anti-CD19 triggering was also observed for low a n t i -B C R concentrations ( Fig. 6 C) . However, the minimal a n t i -B C R concentration needed for day 4 C P M i n d u c t i o n was not significantly lowered by C D 4 0 ligand or a n t i -C D 1 9 mAbs (Fig. 6 C) . Finally, because in vivo C P M expression is restricted to C D 3 8 + leukocytes (9), C D 4 0 + B C R -or C D 1 9 + B C R -s t i m u l a t e d resting B cells were labeled with anti-C D 3 8 and a n t i -C P M mAbs. As illustrated in Fig. 6 D, C P M + in vitro-activated B cells also expressed the C D 3 8 molecule (Fig. 6 /7) ). Noteably, the addition of cytokines (IL-2, IL-3, IL-4, IL-10, or IFN-00 to C D 1 9 + B C R -or C D 4 0 + B C R -a c t i v a t e d B cells only displayed a marginal effect on C P M expression (not shown). Thus, C P M is a G C marker that can be induced by mitogenic concentrations o f a n t i -B C R and specifically requires C D 1 9 or C D 4 0 triggering for optimal expression.
Cotriggering of Resting B Cells through BCR and CD40 Induces Both Phenotypic and Functional GC Features.
Triggering of resting B cells with combinations of different stimuli (CD40 ligand + a n t i -B C R , a n t i -C D 1 9 + a n t i -B C R ) resulted in potent induction of C P M and CD38. Thus, we tested whether these combinations could upregulate other G C markers. As s h o w n in Fig. 7 express high and comparable amounts of Bcl-2 protein. However, unlike CD40-activated lymphocytes, CD40 + BCR.-triggered cells undergo rapid cell death as measured by trypan blue exclusion (Fig. 8 B) . This spontaneous cell death can also be quantified by propidium iodide and HOECHST 33342 double labeling (13) . Using this method, after 20 h in medium, only 14% of CD40 + BCR-triggered cells appear viable (Fig. 8 C, right) , whereas 68% of cells that received only the CD40 triggering are viable ( Fig. 8 C, left) . This rapid loss of viability may be due to apoptotic cell death because a sizeable (14%) proportion of CD40 + BCP,-activated cells exhibits condensed chromatin and an integral plasma membrane structure.
Discussion
Early histophysiological studies have shown that the GC is a T cell-dependent structure. Indeed, individuals with a complete T cell defect do not form GC (22) . The interaction between CD40 on B cells with its ligand on Th cells recently emerged as an essential component of this Th-B cell crosstalk because a defective expression of CD40 or CD40 ligand leads to a GC formation defect (23) (24) (25) (26) . The implication of CD40-CD40 ligand interaction in the GC reaction is further illustrated by the fact that both isotype switching and the somatic mutation processes--two molecular events that take place in GC--are absent in patients displaying the nonfunctional CD40 ligand gene (27-30, D. P, azanajaona, C. Van Kooten, S. Lebeque, J. M. Bridon, S. Ho, S. Smith, R. Callard, J. Banchereau, and F. BriSre, manuscript in preparation). As shown in this report, in vitro CD40 stimulation of B cells leads to several phenotypic alterations that occur in the GC. Thus, in agreement with former reports (10, 11, 31, 32) , CD40 stimulation induces the coexpression of CD95 (FAS), CDS0 (B7.1), CD86 (B7.2), and CD71 surface molecules. In addition, CD40 triggering leads to the disappearance of CD24 antigen which, in vivo, marks B cell entry into the GC (33) . When combined with certain cytokines such as IFN-~ or IFN-% CD40 triggering is also able to induce strong CD38 expression. This result is consistent with a previous report showing that immunoreactive IFN-ix can be detected in GC tingible body macrophages of human secondary lymphoid tissues (34) . A high frequency of spontaneous IFN-"y-producing T cells is also present in human tonsils (35) . These IFN-'g-producing T cells are mainly located in the extrafollicular area (36) , where CD40-L+-activated T ceils are also detected (37) (38) (39) . Accordingly, in vivo CD40 + IFNs stimulation of antigen-specific B lymphocytes could indeed take place in human lymphoid tissues and drive the induction of CD38.
Although it has been clearly demonstrated that antigen is essential for the GC reaction, little is known concerning the site and context of the B cell-antigen encounter. In vitro experiments have shown that antigenic stimulation of B cells is critical for effective Th-B cell collaboration (40) . Indeed, BCR triggering by multivalent antigen appears to be necessary for the induction of CD28 ligands (CD80 or CD86) on the B cell surface (41) . These CD28 ligands are required for full Th cell proliferation and cytokine production, which, in turn, would control B cell blastogenesis. Interestingly, efficient triggering of BCR is also necessary to sensitize B cells to Th cells expressing low (physiological) levels of CD40 ligand (42) . In vivo, this efficient BCR stimulation could be achieved in the presence of accessory cells like follicular dendritic cells (43) retaining the unprocessed antigen on their surface. Here we show that BCR stimulation can contribute to the acquisition of CD38 antigen. In addition, BCR triggering is the only signal tested so far that allows the induction of CPM, a surface membrane enzyme specifically expressed on GC mature B cells (9) . Anti-BCR induction of CPM is further enhanced by anti-CD40 or, to a lesser extent, by anti-CD19 cotriggering. The contribution of CD19 or CD40 molecules to the induction of CPM was specific in that antibodies against six other surface molecules failed to display such an activity (see Fig. 6, A and B) . Recent experiments in mice have shown that CD19 is necessary for the formation of GC in response to T cell-dependent antigens (44) . CD19 is a B cell-restricted type I protein with a large extracytoplasmic portion comprising two Ig-like domains. The CD19 extracellular portion also includes a potential CD77 (globotriaosyl ceramide)-binding site (45) . Together, these structural features suggest that a ligand for CD19 may exist. In addition, CD19 is a major component of the signal transduction complex associated with the CD21 (IFN-0t receptor) molecule (for reviews see references 46, 47) . In our hands, however, IFN-0t or anti-CD21 mAbs displayed only a limited effect on CPM induction, suggesting that, if it plays a role in human GC formation, CD19 might act independently of CD21.
Unlike CD19 + BCR stimulation, CD40 + BCR cotriggering drives resting B lymphocytes to exhibit seven GC phenotypic features, including the lack of surface CD24 and the presence of markers like CD80, CD86, CD7I, CD95, and CD38. The latter could possibly result from anti-BCR-induced endogenous IFN-cl production (48) . However, CD40 + BCR stimulation could not generate CD10 + or CD44-cells, thus suggesting that other stimuli are required for modulating these markers. It should be noted that, in vivo, CD40-CD40 ligand contact is short lasting and tightly regulated. Indeed, within hours after contact, CI)40 is released from APC--presumably through proteolitic cleavage (49)--whereas CD40 ligand is internalized in T cells (50) . Thus, two step culture experiments using CD40 + BCR-prestimulated B cells are in progress to identify the factors responsible for the generation of CD44-or CD10 + B cells. Interestingly, CD40 + BCRactivated B cells undergo spontaneous cell death in medium that is reminiscent of the apoptosis of GC B cells. This in vitro-induced cell death is likely to be the result of continuous triggering of BCR, and is observed on cells exhibiting high levels of Bcl-2 protein. The mechanisms responsible for this cell death induction are unknown and could be dependent upon the expression of other survival/ death genes. Because lymphocytes undergoing in vivo somatic hypermutation are highly susceptible to apoptotic cell death (21), we are presently investigating whether CD40 + BCR~stimulated naive B cells undergo somatic mutation in culture. In conclusion, our results imply that the acquisition ofa GC phenotype requires efficient cotriggering of BCR and CD40. They also show that IFNs or CD19 triggering could contribute to the induction of GC markers in humans. Finally, consistent with earlier reports on freshly isolated GC cells, in vitro acquisition of a GC phenotype renders resting B lymphocytes highly susceptible to spontaneous cell death.
